Core Viewpoint - ST Bailin (002424.SZ) has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which enhances the company's intellectual property protection and competitive edge [1] Group 1: Patent Application Details - The accepted patent application is for a traditional Chinese medicine formulation for treating diabetes or its complications, based on years of research from the company's Tang Ning Tong Luo project [1] - The confidentiality of the patent application covers the formulation composition, production process, and multiple treatment areas, with a protection period aligned with the "secret" confidentiality period under the National Confidentiality Law of the People's Republic of China [1] Group 2: Implications for the Company - The acceptance of this confidential patent will provide comprehensive and tighter core intellectual property protection for the Tang Ning Tong Luo project [1] - If the patent is ultimately granted, it will help the company avoid core technology leakage and accelerate clinical promotion and market conversion, thereby enhancing the company's core competitiveness [1]